Bosutinib

Mechanism

It is an ATP-competitive Bcr-Abl tyrosine-kinase inhibitor with an additional inhibitory effect on Src family kinases (including Src, Lyn and Hck). It has also shown activity against the receptors for platelet derived growth factor and vascular endothelial growth factor. Bosutinib inhibited 16 of 18 imatinib-resistant forms of Bcr-Abl expressed in murine myeloid cell lines, but did not inhibit T315I and V299L mutant cells.

Bosutinib is metabolized through CYP3A4.

Medical uses

Bosutinib received US FDA and EU European Medicines Agency approval in September 2012, and March 2013, respectively for the treatment of adults with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

Contraindications

Bosutinib has two known absolute contraindications, which are: known hypersensitivity to bosutinib and liver impairment.

Interactions

Bosutinib is both a substrate and an inhibitor of P-glycoprotein (P-gp) and CYP3A4. Hence P-gp and CYP3A4 inhibitors may increase plasma levels of bosutinib. Likewise CYP3A4 inducers may reduce plasma concentrations of bosutinib. It may also alter the metabolism and uptake (into the GIT by means of its P-gp inhibitory effects) of other drugs that are substrates for P-gp and CYP3A4.

Notes

References

References

1. (21 June 2022). "Prescription medicines: registration of new chemical entities in Australia, 2014".
2. (September 2024). "Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia". Annals of Hematology.
3. (February 2012). "Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors". Clinical Cancer Research.
4. (2012). "LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]". National Institute of Diabetes and Digestive and Kidney Diseases.
5. (October 2011). "Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib". Blood.
6. (October 2012). "Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial". Journal of Clinical Oncology.
7. (5 September 2012). "Bosulif Approved for Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia".
8. (9 April 2013). "Bosulif : EPAR - Product Information". Pfizer Ltd.
9. (7 June 2013). "Bosulif 100mg and 500mg Tablets - Summary of Product Characteristics (SPC)". Pfitzer Limited.
10. (September 2013). "BOSULIF (bosutinib monohydrate) tablet, film coated [Pfizer Laboratories Div Pfizer Inc]". Pfitzer Inc.
11. "Bosulif (bosutinib) dosing, indications, interactions, adverse effects, and more". WebMD.